Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Halozyme Therapeutics Inc

+ Add to Watchlist

HALOZ:GR

13.049 EUR 0.817 5.89%

As of 15:41:46 ET on 04/30/2015.

Snapshot for Halozyme Therapeutics Inc (HALOZ)

Open: 13.729 Day's Range: 12.832 - 13.847 Volume: 300
Previous Close: 13.866 52wk Range: 4.985 - 15.638 1-Yr Rtn: +150.46%

Stock Chart for HALOZ

No chart data available.
  • HALOZ:GR 13.783
  • 1D
  • 1M
  • 1Y
13.866
Interactive HALOZ Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for HALOZ

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.5030
Est. PEG Ratio -
Market Cap (M EUR) 1,657.43
Shares Outstanding (M) 127.02
30 Day Average Volume 402
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/12/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for HALOZ

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for HALOZ

Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The Company's platform technology is based on recombinant human hyaluronidase plus additional enzymes. Halozyme applies its technology to its proprietary programs and to partnerships with pharmaceutical companies.

Helen I TorleyPresident/CEOAthena CountouriotisChief Medical Officer
Harry J LeonhardtSenior VP/Chief Compliance OfcrDavid A RamsayVP/CFO
More Company Profile & Key Executives for HALOZ

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil